The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | A new machine learning system for prognostication based on gene expression signatures in MCL & PTCL
Adrian Mosquera-Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, comments on the feasibility of using a new machine learning algorithm for prognostication based on gene expression signatures in mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Amgen, AstraZeneca, Janssen, Abbvie, Takeda, Brystol, GSK, Pfizer: Consultancy, Honoraria, Research Funding.
